Q-omics provides the consensus-scored MIR302A profile across patient tissues and cancer cell-line models. MIR302A expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MIR302A is differentially expressed in 2, with the highest sampling consensus in STAD. Additionally, MIR302A RNA expression shows 9,582 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, STAD, and TGCT as cancer lineages where MIR302A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR302A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR302A survival associations across molecular data types. MIR302A RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR302A RNA expression–survival associations across cancer types. High MIR302A expression shows unfavorable associations in UVM, KIRC, THCA and LGG, but favorable associations in HNSC and BRCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify UVM as the clearest survival context for MIR302A RNA expression.
This table summarizes MIR302A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in PRAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR302A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR302A shows higher tumor expression in STAD and PRAD. The STAD box plot shows higher MIR302A RNA expression in tumor versus normal tissue (log2 FC = +0.488, t-test p = .011).
This table shows molecular features associated with MIR302A in patient tissues and cancer cell lines. In patient samples, MIR302A shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
